Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

NCT06312670 is registered in ClinicalTrials.gov with Pedro Barata, MD, MSc as lead sponsor.

NCT NCT06312670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06312670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Lead sponsor
Pedro Barata, MD, MSc
Phase
Phase 2
Overall status
Completed
Start date
May 16, 2024
Completion date
January 9, 2025
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer (mhspc), prostate adenocarcinoma, prostate cancer